GlassScriptPhysician profile
Ronald Tyler Hebert
NPI 1003310897
$5,261.97
in general payments reported to CMS, 2019-2025
38 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.75 · 2021: $310 · 2022: $1,664 · 2023: $1,745 · 2024: $1,138 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,264.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $758.87 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $572.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $520.08 | 2021-2025 | |
| Lilly USA, LLC | $338.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $314.92 | 2021-2024 | Veozah, Myrbetriq |
| Amgen INC. | $313.27 | 2021-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $306.89 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $247.88 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $239.79 | 2022-2025 | |
| Corium, LLC | $235.36 | 2022-2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $177.95 | 2021-2025 | |
| Esperion Therapeutics, INC. | $123.25 | 2022-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.57 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.77 | 2023-2024 | Trulance |
| Dexcom, INC. | $91.39 | 2022-2023 | Dexcom G6 Transmitter |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $86.64 | 2021-2024 | Trintellix |
| Pfizer INC. | $65.46 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $64.17 | 2024 | Gemtesa, Myfembree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.56 | 2022-2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $61.42 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $51.83 | 2022-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $44.77 | 2021-2024 | |
| Noven Therapeutics, LLC | $44.77 | 2023-2025 | Xelstrym |
| Abbott Laboratories | $34.73 | 2023-2024 | Freestyle Libre 3 |
| Lundbeck LLC | $30.04 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $28.41 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $27.02 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.65 | 2022 | |
| Ironshore Pharmaceuticals INC. | $23.72 | 2024 | |
| Axsome Therapeutics, INC. | $23.12 | 2023 | Sunosi |
| Exact Sciences Corporation | $20.21 | 2025 | The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $18.68 | 2024 | Xyosted |
| Eisai INC. | $18.56 | 2023 | |
| Seqirus USA INC | $15.83 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Amarin Pharma, INC. | $15.75 | 2022 | |
| Sanofi Pasteur INC. | $15.11 | 2022 | |
| Bausch Health US, LLC | $14.88 | 2022 | |
| Currax Pharmaceuticals LLC | $13.38 | 2024 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.